Skip to content

facebook.com
twitter.com
t.me
instagram.com
youtube.com

Home
Biotechnology
Medical Technology
Research
Genetics
Press Releases
Contact

Home
Biotechnology
Connect’s Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope

Connect’s Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope

September 15, 2026Posted inBiotechnology

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.

Post navigation

Previous Post

Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech

Next Post

FDA launches pilot program to speed up sluggish phase 1 trials

Recent Posts

Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies
Consolidating Antibody Discovery Data with an AI Platform
FDA launches pilot program to speed up sluggish phase 1 trials
Connect’s Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech

Archives

September 2026
August 2026
July 2026
June 2026
May 2026
April 2026
March 2026
February 2026
January 2026
December 2025
November 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
March 2025
February 2025
January 2025
December 2024
November 2024
October 2024
September 2024
August 2024
March 2024
January 2024
September 2023

Privacy Policy Terms